Bermekimab is under clinical development by XBiotech and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bermekimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bermekimab (Xilonix) is under development for atopic dermatitis. The drug candidate is administered through intravenous and subcutaneous routes. Xilonix is acts by targeting Interleukin 1 alpha. It was also under development for the treatment of unspecified indication, cachexia in patients with advanced colorectal cancer, relapsed/refractory acute myeloid leukemia, relapsed/refractory acute lymphocytic leukemia, relapsed/refractory chronic lymphocytic leukemia (CLL), relapsed/refractory chronic myelocytic leukemia, hidradenitis suppurativa, arterial thrombosis, non-small cell lung cancer, restenosis (Peripheral vascular disease) in patients undergoing percutaneous femoropopliteal revascularization, skin ulcers including pyoderma gangrenosum, moderate to severe plaque psoriasis, type 2 diabetes mellitus, acne vulgaris, systemic scleroderma, advanced pancreatic cancer with cachexia and ovarian cancer.
Natrunix is under development for the treatment of inflammatory joint diseases, including osteoarthritis and rheumatoid arthritis (RA).
XBiotech is biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed for the treatment of metastatic colorectal cancer. XBiotech offers clinical trial activity services, oncology, MRSA, and dermatology related solutions. The company develops a True Human technology to discover and develop targeted antibody candidates. It pipeline includes candidates, which target various therapeutic areas such as pyoderma gangrenosum, plaque psoriasis, influenza and Type II diabetes, among others. It has operations in the US, Switzerland, Japan and Germany. XBiotech is headquartered in Austin, Texas, the US.
For a complete picture of Bermekimab’s drug-specific PTSR and LoA scores, buy the report here.